Last Close
1.40
Aug 14 • 3:59 PM ET Dollar change-0.09 Percentage change(-6.04%)
Aftermarket Close
1.44
Aftermarket • 7:57 PM ET Dollar change+0.04 Percentage change(2.91%)
Aug 14, 12:13 AMCo-Diagnostics files dual 510(k) and CLIA waiver for flu A/B and RSV assay amid liquidity risk
Index
-
Market Cap
8.75M
Enterprise Value
6.90M
Income
-47.06M
Sales
0.52M
Book/sh
2.61
Cash/sh
0.58
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
115
IPO
Jul 12, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
16.83
P/B
0.54
P/C
2.40
P/FCF
-
EV/EBITDA
-
EV/Sales
13.27
Quick Ratio
1.52
Current Ratio
1.81
Debt/Eq
0.14
LT Debt/Eq
0.08
Option/Short
No / Yes
EPS (ttm)
-22.46
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-37.47% -
Sales past 3/5Y
-76.97% -64.54%
EPS Y/Y TTM
33.16%
Sales Y/Y TTM
-9.18%
EPS Q/Q
79.18%
Sales Q/Q
1.98%
Insider Own
5.18%
Insider Trans
0.00%
Inst Own
8.55%
Inst Trans
0.19%
ROA
-149.25%
ROE
-174.77%
ROIC
-342.80%
Gross Margin
-170.74%
Oper. Margin
-5857.07%
Profit Margin
-9100.00%
SMA20
-18.01%
SMA50
-49.06%
SMA200
-68.72%
Trades
Shs Outstand
6.98M
Shs Float
6.62M
52W High
46.50 -96.99%
52W Low
1.26 11.11%
Volatility
7.67% 13.55%
ATR (14)
0.28
RSI (14)
30.29
Beta
2.87
Rel Volume
0.06
Avg Volume
5.59M
Volume
330,417
Perf Week
-7.89%
Perf Month
-43.66%
Perf Quarter
-14.11%
Perf Half Y
-40.43%
Perf YTD
-72.32%
Perf Year
-82.42%
Perf 3Y
-96.41%
Perf 5Y
-99.56%
Perf 10Y
-
Prev Close
1.49
Price
1.40
Change %
-6.04%
Aug-14-26 08:30AM
01:03AM
Aug-13-26 04:01PM
Aug-06-26 09:30AM
Jul-30-26 09:00AM
08:00AM Loading…
Jul-28-26 08:00AM
Jul-22-26 09:00AM
Jul-16-26 09:00AM
Jul-08-26 09:00AM
Jul-01-26 09:00AM
Jun-25-26 09:00AM
Jun-18-26 09:05AM
Jun-11-26 09:00AM
Jun-02-26 09:00AM
May-26-26 01:00PM
09:00AM Loading…
09:00AM
May-19-26 10:54PM
10:34AM
May-15-26 08:30AM
01:02AM
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
Apr-09-26 09:00AM
Apr-02-26 09:00AM
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM
08:00AM Loading…
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA